Adherex Technologies (FENC) Competitors $8.66 +0.49 (+6.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$8.66 0.00 (0.00%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FENC vs. SYRE, AKBA, PHAR, CRON, TRVI, ELVN, ZYME, UPB, MLYS, and IMNMShould you be buying Adherex Technologies stock or one of its competitors? The main competitors of Adherex Technologies include Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Pharming Group (PHAR), Cronos Group (CRON), Trevi Therapeutics (TRVI), Enliven Therapeutics (ELVN), Zymeworks (ZYME), Upstream Bio (UPB), Mineralys Therapeutics (MLYS), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Adherex Technologies vs. Its Competitors Spyre Therapeutics Akebia Therapeutics Pharming Group Cronos Group Trevi Therapeutics Enliven Therapeutics Zymeworks Upstream Bio Mineralys Therapeutics Immunome Spyre Therapeutics (NASDAQ:SYRE) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Is SYRE or FENC more profitable? Spyre Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -35.05%. Adherex Technologies' return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -71.30% -38.69% Adherex Technologies -35.05%N/A -23.92% Which has stronger valuation & earnings, SYRE or FENC? Adherex Technologies has higher revenue and earnings than Spyre Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre TherapeuticsN/AN/A-$208.02M-$3.40-5.11Adherex Technologies$47.54M5.07-$440K-$0.42-20.62 Which has more risk & volatility, SYRE or FENC? Spyre Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Does the media refer more to SYRE or FENC? In the previous week, Adherex Technologies had 16 more articles in the media than Spyre Therapeutics. MarketBeat recorded 16 mentions for Adherex Technologies and 0 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.59 beat Adherex Technologies' score of -0.01 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Spyre Therapeutics Positive Adherex Technologies Neutral Do analysts rate SYRE or FENC? Spyre Therapeutics presently has a consensus price target of $53.40, suggesting a potential upside of 207.25%. Adherex Technologies has a consensus price target of $13.33, suggesting a potential upside of 53.96%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Adherex Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Adherex Technologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of SYRE or FENC? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 15.4% of Spyre Therapeutics shares are held by company insiders. Comparatively, 11.8% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummarySpyre Therapeutics beats Adherex Technologies on 10 of the 16 factors compared between the two stocks. Get Adherex Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FENC vs. The Competition Export to ExcelMetricAdherex TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.24M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-20.6220.8831.1026.05Price / Sales5.07356.38435.79105.95Price / Cash252.9743.1937.7358.48Price / Book-32.078.129.536.61Net Income-$440K-$54.72M$3.26B$265.56M7 Day Performance3.59%2.63%2.09%1.97%1 Month Performance-0.80%2.78%2.81%-0.36%1 Year Performance51.93%11.01%30.56%19.03% Adherex Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FENCAdherex Technologies1.8762 of 5 stars$8.66+6.0%$13.33+54.0%+57.5%$227.24M$47.54M-20.6210Analyst ForecastAnalyst RevisionHigh Trading VolumeSYRESpyre Therapeutics2.905 of 5 stars$15.25+0.6%$53.40+250.2%-29.8%$915.68M$890K-4.4973AKBAAkebia Therapeutics4.0368 of 5 stars$3.35-2.0%$6.75+101.5%+117.0%$906.80M$160.18M-19.70430Positive NewsPHARPharming Group2.4169 of 5 stars$12.10-8.5%$30.00+147.9%+72.3%$906.45M$297.20M-93.08280Gap UpHigh Trading VolumeCRONCronos Group0.7663 of 5 stars$2.67+16.1%N/A+12.6%$882.76M$117.61M53.40450High Trading VolumeTRVITrevi Therapeutics3.1286 of 5 stars$7.32-1.3%$20.38+178.3%+173.6%$870.31MN/A-17.4320Analyst ForecastELVNEnliven Therapeutics2.8713 of 5 stars$18.11+2.4%$41.20+127.5%-9.0%$868.03MN/A-9.4350Insider TradeZYMEZymeworks1.826 of 5 stars$12.44+3.5%$21.43+72.3%+35.3%$866.86M$122.87M-8.29460UPBUpstream Bio2.1487 of 5 stars$16.59+3.7%$56.50+240.6%N/A$862.55M$2.37M0.0038High Trading VolumeMLYSMineralys Therapeutics3.435 of 5 stars$13.19+1.5%$32.25+144.5%+32.1%$847.28MN/A-3.5428Positive NewsIMNMImmunome1.9039 of 5 stars$9.66-0.3%$23.14+139.6%-29.4%$843.47M$9.04M-3.1440News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives Pharming Group Alternatives Cronos Group Alternatives Trevi Therapeutics Alternatives Enliven Therapeutics Alternatives Zymeworks Alternatives Upstream Bio Alternatives Mineralys Therapeutics Alternatives Immunome Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FENC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adherex Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adherex Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access